| |  Online-Ressource |
|---|
| Verfasst von: | Livingstone, Elisabeth [VerfasserIn]  |
|---|
| | Gogas, H. [VerfasserIn] |
|---|
| | Kandolf-Sekulovic, L. [VerfasserIn] |
|---|
| | Meier, F. [VerfasserIn] |
|---|
| | Eigentler, T. K. [VerfasserIn] |
|---|
| | Ziemer, M. [VerfasserIn] |
|---|
| | Terheyden, P. A. M. [VerfasserIn] |
|---|
| | Gesierich, A. H. [VerfasserIn] |
|---|
| | Herbst, R. A. [VerfasserIn] |
|---|
| | Kähler, K. C. [VerfasserIn] |
|---|
| | Ziogas, D. C. [VerfasserIn] |
|---|
| | Mijuskovic, Z. [VerfasserIn] |
|---|
| | Garzarolli, M. [VerfasserIn] |
|---|
| | Garbe, C. [VerfasserIn] |
|---|
| | Roesch, A. [VerfasserIn] |
|---|
| | Ugurel, S. [VerfasserIn] |
|---|
| | Gutzmer, R. [VerfasserIn] |
|---|
| | Grob, J. J. [VerfasserIn] |
|---|
| | Kiecker, F. [VerfasserIn] |
|---|
| | Utikal, Jochen [VerfasserIn] |
|---|
| | Windemuth-Kieselbach, C. [VerfasserIn] |
|---|
| | Eckhardt, S. [VerfasserIn] |
|---|
| | Zimmer, L. [VerfasserIn] |
|---|
| | Schadendorf, Dirk [VerfasserIn] |
|---|
| Titel: | Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma |
|---|
| Titelzusatz: | the ImmunoCobiVem phase 2 randomised trial |
|---|
| Verf.angabe: | E. Livingstone, H. Gogas, L. Kandolf-Sekulovic, F. Meier, T.K. Eigentler, M. Ziemer, P.A.M. Terheyden, A.H. Gesierich, R. A. Herbst, K. C. Kähler, D.C. Ziogas, Z. Mijuskovic, M. Garzarolli, C. Garbe, A. Roesch, S. Ugurel, R. Gutzmer, J.J. Grob, F. Kiecker, J. Utikal, C. Windemuth-Kieselbach, S. Eckhardt, L. Zimmer, D. Schadendorf |
|---|
| E-Jahr: | 2023 |
|---|
| Jahr: | September 2023 |
|---|
| Umfang: | 13 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Online verfügbar: 15. Juni 2023, Artikelversion: 21. Juli 2023 ; Gesehen am 08.08.2024 |
|---|
| Titel Quelle: | Enthalten in: European journal of cancer |
|---|
| Ort Quelle: | Amsterdam [u.a.] : Elsevier, 1992 |
|---|
| Jahr Quelle: | 2023 |
|---|
| Band/Heft Quelle: | 190(2023), Artikel-ID 112941, Seite 1-13 |
|---|
| ISSN Quelle: | 1879-0852 |
|---|
| Abstract: | Aim - ImmunoCobiVem investigated whether a planned switch to atezolizumab after achieving tumour control during run-in with vemurafenib + cobimetinib improves progression-free survival (PFS) and overall survival (OS) compared to continuous targeted therapy (TT) in patients with previously untreated advanced BRAFV600-mutated melanoma. - Methods - In this multicenter phase 2 study, patients received vemurafenib plus cobimetinib. After 3months, patients without progressive disease (PD) were randomly assigned (1:1) to continue vemurafenib + cobimetinib (Arm A) or switch to atezolizumab (Arm B) until first documented PD (PD1). Primary outcome was PFS1 (time from start of run-in until PD1 or death). OS and safety were also assessed. - Results - Of 185 patients enroled between November 2016 and December 2019, 135 were randomly assigned after the run-in period (Arm A, n = 69; Arm B, n = 66). Median PFS1 was significantly longer in Arm A versus Arm B (13.9 versus 5.9months; hazard ratio [HR] 0.55; 95% confidence interval [CI], 0.37-0.84; PStratified=0.001). Median OS was not reached in either arm (HR 1.22; 95%CI, 0.69-2.16; PStratified=0.389); 2-year OS was higher in Arm B versus Arm A (67%; 95%CI, 53-78 versus 58%; 95%CI, 45-70). Grade 3/4 AEs occurred in 55% of patients in Arm A and 64% in Arm B; treatment-related AEs led to discontinuation of any drug in 7% and 9% of patients, respectively. - Conclusion - In patients with BRAFV600-mutated advanced melanoma who achieve tumour control with TT, early switch at 3months to atezolizumab led to rapid loss of tumour control but provided a numerical OS benefit at 2years compared with continued TT. |
|---|
| DOI: | doi:10.1016/j.ejca.2023.112941 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1016/j.ejca.2023.112941 |
|---|
| | Volltext: https://www.sciencedirect.com/science/article/pii/S0959804923002903 |
|---|
| | DOI: https://doi.org/10.1016/j.ejca.2023.112941 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Checkpoint inhibition |
|---|
| | First-line |
|---|
| | Melanoma |
|---|
| | Run-in |
|---|
| | Sequence |
|---|
| | Targeted therapy |
|---|
| K10plus-PPN: | 1898190593 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma / Livingstone, Elisabeth [VerfasserIn]; September 2023 (Online-Ressource)
